Clinical Review | Published:

Milk Thistle (Silybum marianum) for the Therapy of Liver Disease

American Journal of Gastroenterology volume 93, pages 139143 (1998) | Download Citation

Subjects

Abstract

Silymarin, derived from the milk thistle plant, Silybum marianum, has been used for centuries as a natural remedy for diseases of the liver and biliary tract. As interest in alternative therapy has emerged in the United States, gastroenterologists have encountered increasing numbers of patients taking silymarin with little understanding of its purported properties. Silymarin and its active constituent, silybin, have been reported to work as antioxidants scavenging free radicals and inhibiting lipid peroxidation. Studies also suggest that they protect against genomic injury, increase hepatocyte protein synthesis, decrease the activity of tumor promoters, stabilize mast cells, chelate iron, and slow calcium metabolism. In this article we review silymarin's history, pharmacology, and properties, and the clinical trials pertaining to patients with acute and chronic liver disease.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    . The U.S. botanical market—An overview. Herbalgram 1996;36: 49–57.

  2. 2.

    , , . The use of naturopathic remedies for chronic liver disease. Am J Gastroenterol 1996;91: 2654–2655.

  3. 3.

    . Milk thistle: The liver herb. Botanical Press: Capitola, CA, 1992.

  4. 4.

    . A modern herbal, vol. 2. Dover Publications: New York, 1981.

  5. 5.

    . Milk thistle: Silybum marianum. American Botanical Council: Austin, TX, No. 305, 1991.

  6. 6.

    , . Silybum marianum: Mariendistel. In: Bewaehrte Pflanzendrogen in Wissenschaft und Medizin. Notamed Verlag, 1983: 203–215.

  7. 7.

    . Lehrbuch der biologischen Heilmittel, vol I. Georg Thieme Verlag: Leipzig, 1938: 830–836.

  8. 8.

    . Herbal warning. Newsweek, May 6, 1996: 60–68.

  9. 9.

    Herbal roulette. Consumer Reports. Nov 1995: 195–705.

  10. 10.

    . Textbook of advanced herbology. Wild Rose College of Natural Healing Ltd.: Calgary, Alberta, Canada., 1992.

  11. 11.

    , , , et al. Meth find exp Clin Pharmacol 1984;6: 655.

  12. 12.

    , , , et al. Pharmacokinetic studies in IdB 1016, a silybin-phosphatidylcholine complex, in healthy human subjects. Eur J Drug Metab Pharmacokinet 1990;15: 333–338.

  13. 13.

    , , , et al. Med Sci Res 1990;18: 861.

  14. 14.

    , . Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Internat J Clin Pharmacol Therapeutics 1994;32: 614–617.

  15. 15.

    , , , et al. Planta Med 1980;38: 227.

  16. 16.

    , , , et al. Untersuchungen zur Verstoffwechselung und zur Ausscheidung von Silybin bei der Ratte. Arzneimittel-Forsch 1971;21: 1206–1208.

  17. 17.

    . Dtsch Apoth Ztg 1975;115: 1205.

  18. 18.

    , , . Untersuchungen zur Elimination von Silymarin bei cholezystektomierten Patienten. 2. Mitteilung: Biliaere Elimination nach mehrfacher oraler Gabe. Planta Med 1982;45: 216–223.

  19. 19.

    , , . Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittel-Forschung 1992;42: 964–968.

  20. 20.

    . A peculiarity among flavenoids—Silymarin, a compound active on the liver. Proceedings of the International Bioflavonoid Symposium, FRG: Munich 1981: 472.

  21. 21.

    , , . Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol 1994;48: 753–759.

  22. 22.

    , , . Effect of the flavanolignans of Silybum marianum L. on lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacol Res 1992;25: 147–154.

  23. 23.

    , , , et al. Lipid peroxidation and irreversible damage in the rat hepatocyte model: Protection by the silybin-phospholipid complex IdB 1016. Biochem Pharmacol 1992;43: 2111–2115.

  24. 24.

    , , , et al. Inhibitory effect of the flavonoid silymarin on the erythrocyte hemolysis induced by phenyl-hydrazine. Biochem Biophys Res Commun 1985;126: 712–718.

  25. 25.

    , , . Stimulatory effects of Silibinin on the DNA synthesis in partially hepatectomized rat livers: Non-response in hepatoma and other malignant cell lines. Biochem Pharmacol 1986;35: 538–541.

  26. 26.

    , , , et al. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 1995;109: 1941–1949.

  27. 27.

    , , . et al. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-O-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis 1994;15: 1099–1103.

  28. 28.

    . Proprietes pharmacologiques generates de la silybine et de la silymarine chez le rat. Arch Internat de Pharmacodynamie et de Therapie 1975;214: 165–176.

  29. 29.

    , . The effect of silymarin and gamma radiation on nucleic acids in rat organs. J Pharm Pharmacol 1993;45: 910–912.

  30. 30.

    , , . Hepatoprotector action of silymarin in human acute viral hepatitis. Int Res Commun Syst 1977;5: 259.

  31. 31.

    , , . Zur Wirkung von Silymarin bei der Behandlung der akuten Virushepatitis. Med Klin 1978;73: 1060–1065.

  32. 32.

    . Kontrollierte klinische Pruefung von Legalon. Gazz Med Ital 1974;133: 628.

  33. 33.

    , , , et al. The effects of silymarin on experimental phalloidine poisoning. Arzneimittel-Forschung 1975;25: 89–96.

  34. 34.

    , . Phalloidin-antagonisten. 1. Mitteilung:Wirkung von Silybin-derivaten an der isoliert perfundierten Rattenleber. Arzneimittel-Forschung 1975;25: 394–396.

  35. 35.

    , , , et al. Untersuchungen zu Pharmakodynamik, Angriffspunkt und Wirkungsmechanismus von Silymarin, dem antihepatotoxischen Prinzip aus Silybum mar. (L.) gaertn. Arzneimittel-Forsch 1975;25: 82–89.

  36. 36.

    , , , et al. Protection by silybinin against Amanita phalloides intoxication in beagles. Toxicol Appl Pharmacol 1984;73: 355–362.

  37. 37.

    . Natural substances with effects on the liver. In: New natural products and plant drugs with pharmacological, biological or therapeutical activity. Springer-Verag: New York, 1977: 2651–2665.

  38. 38.

    . Silibinin in the treatment of deathcap fungus poisoning. Forum 1984;6: 23–26.

  39. 39.

    , , , et al. Poisoning by the deathcap fungus (Amanita phalloides): Prognostic factors and therapeutic measures. Schweiz Med Wochenschrift 1982;112: 1164–1177.

  40. 40.

    , , , et al. Silymarin in the protection against exogenous noxae. Drugs Exp Clin Res 1981;7: 115–120.

  41. 41.

    , , . Protective effect of Legalon in workers exposed to organic solvents. Acta Med Hung 1988;45: 249–256.

  42. 42.

    , , et al. The effect of silymarin on plasma levels of malondialdehyde in patients receiving long-term treatment with psychotropic drugs. Curr Ther Res 1994;55: 537–545.

  43. 43.

    , , , et al. Effetti terapeutici della silimarina nelle epatopatie croniche indotte da psicofarmaci. Gaz Med It 1976;135: 236–251.

  44. 44.

    , , , et al. La silimarina in gravidanza e nel trattamento contraccettivo ormonale. Rilievi ematochimici ed ultrastrutturali su modello sperimentale. Archivio Pr Le Scienze Mediche 1979;136: 443–454.

  45. 45.

    . Postoperatives Verhalten der Serumcholinesterase und anderer Leberenzyme. Med Klin 1973;68: 809.

  46. 46.

    , , , et al. Hepatoprotective activity of silymarin (Legalon) therapy in patients with chronic liver disease. Orvosi Hetilap 1989;130: 2723–2727.

  47. 47.

    , . Effect of silymarin on chemical, functional and morphological alterations of the liver: A double-blind study. Scand J Gastroenterol 1982;17: 517–521.

  48. 48.

    , . Nachweis der therapeutischen Wirksamkeit von Legalon bei toxischen Lebererkrankungen im Doppelblindversuch. Therapiewoche 1980;30: 5589–5594.

  49. 49.

    , , , et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 1989;9: 105–113.

  50. 50.

    , , et al. Therapy of toxic liver pathologies with Legalon. Z Klin Med 1992;47: 87–92.

  51. 51.

    , , . Ergebnisse zweier Doppelblind-studien zur Wirksamkeit von Silymarin bei chronischer Hepatitis. Leber Magen Darm 1977;7: 318–323.

Download references

Author information

Affiliations

  1. Division of Gastroenterology, Oregon Health Sciences University, Portland, Oregon

    • Kenneth Flora
    • , Martin Hahn
    • , Hugo Rosen
    •  & Kent Benner

Authors

  1. Search for Kenneth Flora in:

  2. Search for Martin Hahn in:

  3. Search for Hugo Rosen in:

  4. Search for Kent Benner in:

Corresponding author

Correspondence to Kenneth Flora.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1111/j.1572-0241.1998.00139.x

Further reading